Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

Pages: 66 Published: March 01, 2014 Report Code: GDHC2030CTIDB

GlobalData's clinical trial report, “Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations

– Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

– Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to Buy

– Understand the dynamics of a particular indication in a condensed manner

– Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

– Obtain discontinued trial listing for trials across the globe

– Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 7

Report Guidance 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Unaccomplished Trials of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 25

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials 30

Prominent Drugs 31

Latest Clinical Trials News on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 32

Apr 20, 2011: Advancell Initiates Clinical Phase IIb Study Of ATH008 In Hand-foot Syndrome 32

Clinical Trial Profiles 33

Clinical Trial Overview of Top Companies 33

F. Hoffmann-La Roche Ltd. 33

Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 33

Merck & Co., Inc. 34

Clinical Trial Overview of Merck & Co., Inc. 34

Cahaba Pharmaceuticals 35

Clinical Trial Overview of Cahaba Pharmaceuticals 35

Advancell 36

Clinical Trial Overview of Advancell 36

Clinical Trial Overview of Top Institutes / Government 37

Northwestern University 37

Clinical Trial Overview of Northwestern University 37

Cambridge University Hospitals NHS Foundation Trust 38

Clinical Trial Overview of Cambridge University Hospitals NHS Foundation Trust 38

Asan Medical Center 39

Clinical Trial Overview of Asan Medical Center 39

North Central Cancer Treatment Group 40

Clinical Trial Overview of North Central Cancer Treatment Group 40

Sun Yat-sen University 41

Clinical Trial Overview of Sun Yat-sen University 41

Case Comprehensive Cancer Center 42

Clinical Trial Overview of Case Comprehensive Cancer Center 42

Duke University 43

Clinical Trial Overview of Duke University 43

West Virginia University 44

Clinical Trial Overview of West Virginia University 44

University of California, San Francisco 45

Clinical Trial Overview of University of California, San Francisco 45

University of Wisconsin Madison 46

Clinical Trial Overview of University of Wisconsin Madison 46

Five Key Clinical Profiles 47

Appendix 63

Abbreviations 63

Definitions 63

Research Methodology 64

Secondary Research 64

About GlobalData 65

Contact Us 65

Disclaimer 65

Source 66

List of Tables

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region, 2014* 8

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2014* 26

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 33

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 34

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cahaba Pharmaceuticals, 2014* 35

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Advancell, 2014* 36

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 37

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cambridge University Hospitals NHS Foundation Trust, 2014* 38

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 39

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 40

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 41

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 42

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 43

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by West Virginia University, 2014* 44

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 45

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Wisconsin Madison, 2014* 46

List of Figures

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 11

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21

Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31

GlobalData Methodology 64

$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods